Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy
I'm PortAI, I can summarize articles.
Coya Therapeutics Inc. reported positive results from a study on low-dose IL-2 and CTLA4-Ig combination therapy for Frontotemporal Dementia (FTD). The 22-week trial showed increased regulatory T cell numbers and cognitive stability in nine patients. Mild erythema was the most common adverse event, with no serious issues reported. Coya plans to advance this combination therapy, COYA 302, into a phase 2 clinical trial for FTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments